In conjunction with PEX and immunosuppression, CABLIVI significantly reduced potentially fatal or serious aTTP-related events2
| CABLIVI + PEX + Immunosupression
n=72, n (%)* | Placebo + PEX + Immunosuppression
n=73, n (%) | |
| aTTP-related death | 0 | 3 (4.1%) |
| Recurrence during treatment† | 3 (4.2%) | 28 (38.4%) |
| ≥1 major thromboembolic event | 6 (8.5%) | 6 (8.2%) |
| Total | 9 (12.7%) | 36 (49.3%) |
.2025-05-01-13-12-44.svg)
- 4 aTTP-related deaths occurred during the trial, including 1 non–treatment-related death in the CABLIVI group during the treatment-free follow-up period and 3 deaths in the placebo group during the treatment period2
CABLIVI led to a 74% reduction in the composite endpoint vs PEX and immunosuppression alone (P<0.001)1,2
*Based on 71 patients who received at least 1 dose of study drug.5
†Exacerbation defined as thrombocytopenia after initial recovery of platelet count (platelet count ≥150,000/μL with subsequent stop of daily PEX within 5 days) that required reinitiation of daily PEX during the 30-day post daily PEX period.5